Danish drugmaker H Lundbeck A/S is working with financial advisers to explore a potential takeover of Chicago-based commercial-stage Xeris Biopharma, Bloomberg reported, citing people familiar with the matter. The discussions remain preliminary and may not lead to a formal transaction. Xeris shares have risen almost 20% over the past 12 months, valuing the company at about $1.8 billion, compared with Lundbeck’s market capitalization of roughly 43.3 billion Danish kroner ($6.6 billion). Xeris spokeswoman said the company is "not for sale" and remains focused on developing and commercializing its portfolio. The company has three approved treatments, including Recorlev for Cushing’s syndrome, and is developing a once-weekly hypothyroidism injection. In August, Xeris reported second-quarter revenue of $91 million, driven by Recorlev. Lundbeck’s portfolio is centered on psychiatric and neurological conditions, including depression, psychosis, migraine, epilepsy, Parkinson’s disease and schizophrenia, with Rexulti and Vyepti among its largest products. Any deal would broaden Lundbeck’s exposure to rare endocrine disorders and specialized drug-delivery technologies, but investors will be watching for a formal proposal or confirmation that Xeris will remain independent.